Mammalian Cell Resource Core

哺乳动物细胞资源(MCR)核心旨在为三个主要领域的项目提供服务：(1)根据项目负责人的指定，对选定的哺乳动物细胞系进行生长特性、化学和辐射敏感性(克隆存活)的鉴定，以及对遗传标记(如NEC)所赋予的耐药表型的验证；MCR将成为所有项目的冷冻保存的、具有特征的、无支原体的哺乳动物细胞系的储存库，确保整个方案的质量控制，并为项目间的比较提供信心。(2)根据个别项目的要求，从特定的哺乳动物细胞系中制备哺乳动物细胞提取物。(3)根据个别项目的要求，为构建专门的细胞系(即基因敲除和敲除)提供咨询和援助。因此，《公约》有三个具体目标： (1)为确保质量控制和确保项目间实验比较的有效性，按要求确定、维护和分配构成本计划的项目所使用的哺乳动物细胞系； (2)根据项目的要求，为哺乳动物细胞系准备小的(最多2升)定制提取物，或从个别项目提供的商业购买细胞中制备大的(最多50升)提取物； (3)酌情为专门化哺乳动物细胞系的构建和鉴定提供咨询和技术援助，例如shRNA敲除细胞系、基因中断(敲除)细胞系和经基因修饰的细胞系(例如，补充微型基因的细胞系、缺乏aprt和hprt的变异体等)。

The Mammalian Cell Resource (MCR) Core Is designed to serve the Projects comprising the Program in three major areas: (1) To characterize selected mammalian cell lines, as designated by the Project Leaders, with respect to growth characteristics, chemical and radiation sensitivities (clonogenic survival), and verification of drug-resistance phenotypes conferred by genetic markers (e.g., NEC); the MCR will then act as a repository of cryopreserved, characterized mammalian cell lines, free of mycoplasma, for all Projects, ensuring quality control throughout the Program and providing confidence for inter-Project comparsions. (2) To prepare mammalian cell extracts from specific mammalian cell lines as requested by the individual Projects. (3) To provide advice and assistance for the construction of specialized cell lines (i.e., gene knockdown and knock-out) as requested by individual Projects. Thus there are three Specific Aims of the MCR: (1) To characterize, maintain, and distribute as requested mammalian cell lines which are used by the Projects constituting the Program, for the purposes of ensuring quality control and assuring the validity of inter-Project experimental comparisons; (2) To prepare small (up to 2-liter) custom extracts for mammalian cell lines as requested by the Projects, or large (up to 50-liter) extracts from commercially purchased cells provided by individual Projects; (3) To provide advice and technical assistance as appropriate for the construction and characterization of specialized mammalian cell lines such as shRNA knock-down cell lines, gene disruption (knock-out) cell lines, and cell lines with genetic modifications (e.g., minigene-complemented cell lines, APRT- and HPRT-deficient variants, etc.).